SRPT
Sarepta Therapeutics, Inc.
Biotechnology · Healthcare · United States
18.42
close · 2026-08-13
value
85
cheaper than peers85
quality
46
stronger fundamentals46
ranked against
Biotechnology (commercial)
value
quality
101 peerswide variation
Value inputs
| measure | company | vs peers |
| price to sales | 0.92× | 99 |
| forward P/E | 7.16× | 97 |
| price to book | 1.27× | 89 |
| EV to EBITDA | 42.50× | 24 |
4 of 12 measures available
Quality inputs
| measure | company | vs peers |
| operating margin | 13.0% | 77 |
| return on equity | -9.5% | 71 |
| debt to equity | 69.5% | 27 |
| revenue growth | -34.3% | 23 |
4 of 4 measures available
Facts
| market cap | $2B |
| free cash flow | $22.1M |
| employees | 835 |
| first trade | 1997-06-04 |
| next earnings | 2026-08-05 |
| fundamentals updated | 2026-08-10 |